Janssen / J&J
Titusville, New Jersey
Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, develops treatments across immunology, oncology, and neuroscience. Their immunology portfolio includes Stelara (ustekinumab), Tremfya (guselkumab), and Simponi (golimumab) — major biologics for psoriasis, IBD, and inflammatory arthritis. Janssen also has a strong oncology portfolio.
Drugs
Hub Program — Janssen CarePath
- ✓Insurance verification and prior authorization support
- ✓Copay savings program (eligible patients may pay as little as $5/dose)
- ✓Patient assistance program for uninsured/underinsured patients
- ✓Nurse educator support
- ✓Infusion coordination and site-of-care assistance
Patient Assistance
Copay Assistance
Janssen CarePath Savings Program can reduce copays to as little as $5 per dose for eligible commercially insured patients on Stelara, Tremfya, Simponi, and other Janssen products.
Patient Assistance Program (PAP)
Janssen Patient Assistance Foundation provides free medication to qualifying patients without adequate insurance coverage.
Denied a Janssen / J&J Drug?
Ellen can decode your denial, identify the specific reason, and generate a personalized appeal letter — free.